<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7102522/results/search/test_trace/results.xml">
  <result pre="therapies. Introduction Coronaviruses (CoVs) primarily cause multiple respiratory and intestinal" exact="infection" post="in humans and animals [1]. Although the history of"/>
  <result pre="in the Republic of Korea in 2015 [23]. The virus" exact="infection" post="was majorly observed in adults, although it can affect"/>
  <result pre="virus entry at the cell membrane during HCoV-229E and SARS-CoV" exact="infection" post="39, 40, 41. Upon the entry, the viral particle"/>
  <result pre="OR = 26.0, 95% CI = 4.4–154.8). However, disseminated fungal" exact="infection" post="and avascular osteonecrosis occurred following the prolonged systemic corticosteroid"/>
  <result pre="interferon α-2a resolved viremia within 2 days after commencement of" exact="treatment" post="in a patient with severe MERS. Patients with severe"/>
  <result pre="to treat coronavirus infections.To speed up the discovery of potential" exact="treatment" post="options for human pathogenic coronaviruses, two general approaches were"/>
  <result pre="have been employed in the management of patients with MERS-CoV" exact="infection" post="[63]. Recently, several research groups reported the discovery of"/>
  <result pre="mycophenolate mofetil, mycophenolic acid, phenazopyridine, and pyrvinium pamoate) from HTS" exact="screening" post="as broad-spectrum inhibitors according to their strong inhibition of"/>
  <result pre="(7), chlorpromazine (8), loperamide (9) and lopinavir (10) from the" exact="screening" post="of FDA approved drugs library (Fig. 4) [65]. They"/>
  <result pre="[68]. Chlorpromazine (8) was another hit compound resulted from the" exact="screening" post="and inhibited the replication of MERS-CoV with an EC50"/>
  <result pre="Chlorpromazine (8) is the first antipsychotic drug developed for the" exact="treatment" post="of schizophrenia [69] and mechanistically it inhibited the clathrin-mediated"/>
  <result pre="is an orally available small molecule drug used for the" exact="treatment" post="of tumor malignancies through the Src-family of tyrosine kinases"/>
  <result pre="gemcitabine, a deoxycytidine analog that is commonly used for the" exact="treatment" post="of cancers 77, 78 showed a synergistic anti-viral effect"/>
  <result pre="agent lopinavir (10) were able to inhibit both MERS-and SARS-CoVs" exact="infection" post="in the low-micromolar range and was linear with the"/>
  <result pre="was identified as a potential anti-MERS-CoV drug by a high-throughput" exact="screening" post="approach and has a potent anti-MERS-CoV activity in vitro[83]."/>
  <result pre="primate model did not provide a positive result as the" exact="treatment" post="of MERS-CoV infected common marmosets with mycophenolic acid had"/>
  <result pre="that alisporivir inhibits MERS- and SARS-CoV replication by cell-culture based" exact="screening" post="assays relying on the rapid cytopathic effect (CPE) observed"/>
  <result pre="both PLpro enzymes of MERS-CoV and SARS-CoV through a high-throughput" exact="screening" post="of molecule library containing 25,000 chemical entities [96]. As"/>
  <result pre="analogs were reported to combat CoVs by targeting 3CLpro[106]. The" exact="screening" post="of peptidomimetics (57–60; see Fig. 9) which contains a"/>
  <result pre="coronaviral RNA synthesis and showed potent antiviral activity of MERS-CoV" exact="infection" post="with remarkable efficacy [126]. Host-based anti-CoV treatment options The"/>
  <result pre="activity of MERS-CoV infection with remarkable efficacy [126]. Host-based anti-CoV" exact="treatment" post="options The host innate interferon response is crucial for"/>
  <result pre="response is crucial for the control of viral replication after" exact="infection" post="[127]. Although CoVs can suppress the interferon response for"/>
  <result pre="interferon response for immune evasion, they remain susceptible to interferon" exact="treatment" post="in vitro128, 129. The interferon response can be augmented"/>
  <result pre="effective antivirals in clinical trials at early stages of the" exact="infection" post="83, 84. Nitazoxanide (89, Fig. 13 ) is another"/>
  <result pre="in Phase II and Phase III clinical trials for the" exact="treatment" post="of HCV infection and influenza and has a good"/>
  <result pre="and Phase III clinical trials for the treatment of HCV" exact="infection" post="and influenza and has a good safety profile 132,"/>
  <result pre="other cell signaling pathways have been identified as potential anti-CoV" exact="treatment" post="targets. Cyclophilins interact with SARS-CoV nsp1 to modulate the"/>
  <result pre="anti-DPP4 mAbs inhibit MERS-CoV cell entry in vitro[147]. For the" exact="treatment" post="of SARS-CoV, small-molecule entry inhibitors such as N-(2-aminoethyl)-1-aziridineethanamine (93,"/>
  <result pre="Fig. 13) could inhibit more than 90% of MERS-CoV pseudovirus" exact="infection" post="in NBL-7 and Huh-7 cells by interrupting the entry"/>
  <result pre="and was considered as an alternative to ribavirin/IFN combinations for" exact="treatment" post="of HCV infections [169] Mizoribine exerts its activity through"/>
  <result pre="analog prodrug. It was developed by Gilead Sciences as a" exact="treatment" post="for Ebola virus disease and Marburg virus infections, though"/>
  <result pre="cells by more than four orders of magnitude, warranting further" exact="testing" post="of the efficacy of remdesivir against Nipah virus infection"/>
  <result pre="further testing of the efficacy of remdesivir against Nipah virus" exact="infection" post="in vivo. In contrast, to control animals, which all"/>
  <result pre="the lethal challenge, indicating that remdesivir represents a promising antiviral" exact="treatment" post="for Nipah virus infection also [171]. Conclusions Human coronaviruses"/>
  <result pre="that remdesivir represents a promising antiviral treatment for Nipah virus" exact="infection" post="also [171]. Conclusions Human coronaviruses utilizes host cellular components"/>
  <result pre="coronaviral agents have been identified through various approaches, no specific" exact="treatment" post="is currently available for HCoVs, to date. One of"/>
  <result pre="HKU1: a report of 6 CasesClin. Infect. Dis.42200663463916447108 9KanwarA.Human coronavirus-HKU1" exact="infection" post="among adults in Cleveland, OhioOpen Forum Infect Dis.422017ofx05228616442 10PeneF.Coronavirus"/>
  <result pre="Infect. Dis.37200392993213130404 11WalshE.E.Clinical impact of human coronaviruses 229E and OC43" exact="infection" post="in diverse adult populationsJ. Infect. Dis.20820131634164223922367 12GorseG.J.Human coronavirus and"/>
  <result pre="Disorders Drug Targets.720075966 16ArbourN.Neuroinvasion by human respiratory coronavirusesJ. Virol.7420008913892110982334 17ArbourN.Persistent" exact="infection" post="of human oligodendrocytic and neuroglial cell lines by human"/>
  <result pre="cell lines by human coronavirus 229EJ. Virol.7319993326333710074187 18JacomyH.Human coronavirus OC43" exact="infection" post="induces chronic encephalitis leading to disabilities in BALB/C miceVirology349200633534616527322"/>
  <result pre="disabilities in BALB/C miceVirology349200633534616527322 19VabretA.An outbreak of coronavirus OC43 respiratory" exact="infection" post="in Normandy, FranceClin. Infect. Dis.36200398598912684910 20SmutsH.Human coronavirus NL63 infections"/>
  <result pre="April 2019).2017 25World Health OrganizationClinical mamagment of severe acute respiratory" exact="infection" post="when MERS-CoV infection is suspected: interim guidanceAvailable at: http://www.who.int/iris/handle/10665/178529"/>
  <result pre="Health OrganizationClinical mamagment of severe acute respiratory infection when MERS-CoV" exact="infection" post="is suspected: interim guidanceAvailable at: http://www.who.int/iris/handle/10665/178529 (Accessed 17 April"/>
  <result pre="45Mair-JenkinsJ.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the" exact="treatment" post="of severe acute respiratory infections of viral etiology: a"/>
  <result pre="J. Infect. Dis.202014424624406736 48KhalidM.Ribavirin and interferon-α-2b as primary and preventive" exact="treatment" post="for Middle East respiratory syndrome coronavirus (MERS-CoV): a preliminary"/>
  <result pre="serological analysis of a recent Middle East respiratory syndrome coronavirus" exact="infection" post="case on a triple combination antiviral regimenInt. J. Antimicrob."/>
  <result pre="on a triple combination antiviral regimenInt. J. Antimicrob. Agents44201452853225288266 51ChengV.C.Medical" exact="treatment" post="of viral pneumonia including SARS in immunocompetent adultJ. Infect.49200426227315474623"/>
  <result pre="pneumonia including SARS in immunocompetent adultJ. Infect.49200426227315474623 52ChengV.C.Clinical management and" exact="infection" post="control of SARS: lessons learnedAntiviral Res.100201340741923994190 53WongS.S.The management of"/>
  <result pre="cohort studyHong Kong Med. J.9200339940614660806 55ChuC.M.Role of lopinavir/ritonavir in the" exact="treatment" post="of SARS: initial virological and clinical findingsThorax59200425225614985565 56LoutfyM.R.Interferon alfacon-1"/>
  <result pre="[735_TD$DIFF]virusspecific and broad-spectrum inhibitorsAntiviral Res.101201410511224269477 63McIntoshK.Middle East respiratory syndrome coronavirus:" exact="treatment" post="and prevention2017https://www.uptodate.com/contents/middle-east-respiratory-syndrome-coronavirus-virology-pathogenesis-and-epidemiology 64[741_TD$DIFF]ShenHigh-throughput screening and identification of potent broad-spectrum"/>
  <result pre="Res.101201410511224269477 63McIntoshK.Middle East respiratory syndrome coronavirus: treatment and prevention2017https://www.uptodate.com/contents/middle-east-respiratory-syndrome-coronavirus-virology-pathogenesis-and-epidemiology 64[741_TD$DIFF]ShenHigh-throughput" exact="screening" post="and identification of potent broad-spectrum inhibitors of coronavirusesJ. Virol.93122019e000231930918074"/>
  <result pre="agentsPLoS One82003e60579 68PorottoM.Simulating henipa virus multi cycle replication in a" exact="screening" post="assay leads to identiﬁcation of a promising candidate for"/>
  <result pre="to identiﬁcation of a promising candidate for therapyJ. Virol.8320095148515519264786 69[620_TD$DIFF]MiyamotoS.Pharmacological" exact="treatment" post="of schizophrenia: a critical review of the pharmacology and"/>
  <result pre="Infect.67201360661624096239 84ChanJ.F.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV" exact="infection" post="in a non-human primate model of common marmosetJ. Infect."/>
  <result pre="MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus" exact="infection" post="in a mouse modelVirus Res.228201771327840112 88MielechA.M.MERS-CoV papain-like protease has"/>
  <result pre="inhibitorsBioorg. Med. Chem.2420163035304227240464 115KimY.Reversal of the progression of fatal coronavirus" exact="infection" post="in cats by a broad-spectrum coronavirus protease inhibitorPLoS Pathog.122016e1005531"/>
  <result pre="for pathogenesis and treatmentJ. Gen. Virol.9420132679269024077366 129JossetL.Cell host response to" exact="infection" post="with novel human coronavirus EMC predicts potential antivirals and"/>
  <result pre="coronavirusmBio42013e00165–e00113 130HaagmansB.L.Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaquesNat. Med.10200429029314981511 131HartB.J.Interferon-β and mycophenolic acid are potent"/>
  <result pre="infection: a retrospective cohort studyLancet Infect. Dis.1420141090109525278221 137ChengV.C.Clinical management and" exact="infection" post="control of SARS: lessons learnedAntiviral Res.100201340741923994190 138FalzaranoD.Inhibition of novel"/>
  <result pre="randomized, double blind, placebo-controlled study of nitazoxanide monotherapy for the" exact="treatment" post="of patients with chronic hepatitis C genotype 4Aliment. Pharmacol."/>
  <result pre="replication by cyclophilin inhibitorsViruses520131250126023698397 145DyallJ.Repurposing of clinically developed drugs for" exact="treatment" post="of Middle East respiratory syndrome coronavirus infectionAntimicrob. Agents Chemother.5820144885489324841273"/>
  <result pre="and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus" exact="infection" post="as identified by temporal kinome analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition"/>
  <result pre="analysisAntimicrob. Agents Chemother.5920151088109925487801 147OhnumaK.Inhibition of Middle East respiratory syndrome coronavirus" exact="infection" post="by anti-CD26 monoclonal antibodyJ. Virol.872013138921389924067970 148HuentelmanM.J.Structure-based discovery of a"/>
  <result pre="a lethal Cryptosporidium parvum infectionAntimicrob. Agents Chemother.5720136063607324060869 152VermeireJ.J.Cure of hookworm" exact="infection" post="with a cysteine protease inhibitorPLoS Negl. Trop. Dis.62012e168022802972 153BurkardC.Atp1a1-mediated"/>
  <result pre="signaling inhibits coronavirus entry into host cellsJ. Virol.8920154434444825653449 154KimJ.Y.Safe, high-throughput" exact="screening" post="of natural compounds of mers-cov entry inhibitors using a"/>
  <result pre="the family CoronaviridaeJ. Virol.8420102511252120032190 160BartonC.Activity of and effect of subcutaneous" exact="treatment" post="with the broad spectrum antiviral lectin griffithsin in two"/>
 </snippets>
</snippetsTree>
